Cargando…

Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist

Nonpeptide thrombopoietin receptor (TPOR/MPL) agonists, such as eltrombopag, have been used to treat thrombocytopenia of various aetiologies. Here, we investigated the pharmacological properties of hetrombopag, a new orally active small‐molecule TPOR agonist, in preclinical models. Hetrombopag speci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Chengying, Zhao, Huajun, Bao, Xubin, Fu, Haoyu, Lou, Liguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201220/ https://www.ncbi.nlm.nih.gov/pubmed/30156363 http://dx.doi.org/10.1111/jcmm.13809

Ejemplares similares

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
por: Mei, Heng, et al.
Publicado: (2021)

Pharmacologic characterization of fluzoparib, a novel poly(ADP‐ribose) polymerase inhibitor undergoing clinical trials
por: Wang, Lei, et al.
Publicado: (2019)

Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models
por: Long, Fei, et al.
Publicado: (2019)

Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants
por: Gao, Mingzhao, et al.
Publicado: (2019)

Thrombopoietin receptor agonists: ten years later
por: Ghanima, Waleed, et al.
Publicado: (2019)

Effect of Thrombopoietin Receptor Agonist on Pregnant Mice
por: Nakai, Kensaku, et al.
Publicado: (2022)

Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia
por: Bastida, José María, et al.
Publicado: (2021)

Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
por: Erickson-Miller, Connie L, et al.
Publicado: (2009)

Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin
por: Xie, Chengying, et al.
Publicado: (2017)

Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia
por: Garzon, Angelica Maria, et al.
Publicado: (2015)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists
por: Nilles, Kathy M., et al.
Publicado: (2019)

Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
por: Shin, Jiwon, et al.
Publicado: (2023)

Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, in Rats by UPLC-MS/MS
por: Wang, Bo, et al.
Publicado: (2020)

Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis
por: Guo, Jian-Chun, et al.
Publicado: (2017)

Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
por: González-Porras, José R., et al.
Publicado: (2019)

Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists
por: Gilreath, Jeffrey, et al.
Publicado: (2021)

Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience
por: Fattizzo, Bruno, et al.
Publicado: (2022)

A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists
por: Khan, Meaghan, et al.
Publicado: (2010)

Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever?
por: Roy, Sayak
Publicado: (2019)

Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review
por: Agarwal, Nikki, et al.
Publicado: (2021)

Off-Label Use of Thrombopoietin Receptor Agonists: Case Series and Review of the Literature
por: Capecchi, Marco, et al.
Publicado: (2021)

Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
por: Drillet, Gaëlle, et al.
Publicado: (2022)

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
por: Xie, Chengying, et al.
Publicado: (2018)

SHR‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met
por: Tong, Mengya, et al.
Publicado: (2019)

The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin
por: Varghese, Leila N., et al.
Publicado: (2017)

The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation
por: Vogel, Jens-Uwe, et al.
Publicado: (2019)

P1666: EFFECT OF AGONISTS TO THROMBOPOIETIN RECEPTORS ON PLATELET GLYCOME OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Monzón Manzano, E., et al.
Publicado: (2022)

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
por: Rainone, Michael, et al.
Publicado: (2023)

PB2609: 14 YEARS OF EXPERIENCE WITH THROMBOPOIETIN RECEPTOR AGONISTS IN A SINGLE CENTER
por: Garcia-Pallarols, Francesc, et al.
Publicado: (2023)

PB2606: REAL-WORLD EXPERIENCE OF HETROMBOPAG IN RELAPSE AND REFRACTORY IMMUNE THROMBOCYTOPENIA
por: Feng, Yimei, et al.
Publicado: (2023)

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
por: Jurczak, Wojciech, et al.
Publicado: (2018)

Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia
por: Xie, Chengying, et al.
Publicado: (2017)

Avatrombopag, an oral thrombopoietin receptor agonist: results of two double‐blind, dose‐rising, placebo‐controlled Phase 1 studies
por: Kuter, David J., et al.
Publicado: (2018)

Successful Treatment with Thrombopoietin Receptor Agonist in Avoiding Splenectomy for Patients with Chronic Refractory Immune Thrombocytopenia
por: Khalafallah, Alhossain, et al.
Publicado: (2012)

Development and validation of a LC–MS/MS method for quantification of hetrombopag for pharmacokinetics study
por: Chen, Tao, et al.
Publicado: (2015)

NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations
por: Zhao, Jie, et al.
Publicado: (2014)

In and out: Traffic and dynamics of thrombopoietin receptor
por: Roy, Anita, et al.
Publicado: (2021)

Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters
por: Katsube, Takayuki, et al.
Publicado: (2020)

Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag
por: Abdela, Jemal
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t0donrig3c61nob2r13smgk5n1